Table of Contents Table of Contents
Previous Page  318 / 812 Next Page
Information
Show Menu
Previous Page 318 / 812 Next Page
Page Background

S314

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

revolutionized the life of ill persons, creating antipsychotics, the

element around which their entire evolution orbits.

Objectives

Establishment of an eventual change in the evolu-

tion of patients, in the 1st or 2nd phase, on the three underscores

of PANSS, according to their treatment; establishing the election

treatment medication.

Aims

Using PANSS hetero-assessment scale we had as purpose

the category evaluation of phenomena related to schizophrenia

under two treatment methods.

Methods

The 40 patients were divided in two groups with

distinct treatments; performance of an initial clinical interview, fol-

lowed by a second interview at an interval of 2 weeks, having as

purpose to notice an eventual change in the evolution of patients,

according to the type of treatment used. Half of them were follow-

ing a treatment with conventional antipsychotic, and the other part

an atypical antipsychotic treatment.

Results

There are no significant evolutional differences between

scores on the positive scale and on the general scale, as regards

the interval of two weeks during which PANSS scale was repeated.

As regards the results of the negative scale, it is highlighted the

evolution of schizophrenia on the negative scale, in relation with

the atypical antipsychotic treatment underlying its efficiency.

Conclusions

We have noticed that the only change of evolution

occurred on the negative scale of symptoms.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.681

EW564

Long term cognitive training

associated with psychotropic

medication – an improvement in

schizophrenic life

S. Trifu

1 ,

, A .I

. Trifu

2

1

UMF Carol Davila, Psychiatry, Bucharest, Romania

2

Institute for Military Medicine, Education, Bucharest, Romania

Corresponding author.

Introduction

Schizophrenia is a condition of chronically evolv-

ing cognitive invalidation. The average debut for the paranoid form

is the third decade of life, affecting the social and family evolu-

tion through deficiencies in the mnesic prosexic area and that of

thinking.

Objectives

Association of psychotropic medication with long-

term cognitive training; distance (home) training and monitoring

(visual via Internet); development of dual treatment procedure and

medical protocol.

Aims

Impact of long-term cognitive training on young

schizophrenic patients to improve their quality of life.

Methods

Twenty schizophrenic patients (aged 25 to 30) with a

family member were committed to the Psychiatric Hospital for 10

days, were taught to utilize a set of computerized cognitive tests

from the second day of treatment. The cognitive training aimed

at developing: attention (focus on concentration, stability, selec-

tivity and distributive action), memory (retention and evoking)

and thinking (superior cognition, organizing, sequencing, planning,

operational control) After being released, the patients continued

their training practice (at home) under the supervision of family

member.

Results

Cognitive markers analyzed were maintained and

improved, the adapting and social functioning, the family cohesion

finely increased. The direct and indirect costs of hospitalization per

patient decreased, the inpatient care periodwas kept to aminimum

(10 days), the further followup being done outpatient, thereforewe

managed to obtain a better supervision of the patient in time.

Conclusions

For young schizophrenic patients, in their first psy-

chotic episodes, the association between psychotropic medication

and cognitive computerized training, reduces the post process

defect.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.682

EW565

Role of rs6313 and rs1799978 variants

as pharmacogenomic biomarkers in

Greek, Italian and Croatian

schizophrenia patients

E.E. Tsermpini

1 ,

, K. Assimakopoulos

2

, M. Skokou

2

, P. Gourtzis

2

,

G. Iconomou

2

, G. Patrinos

1

1

University of Patras, Department of Pharmacy, Patras, Greece

2

University of Patras, Department of Medicine, Patras, Greece

Corresponding author.

Introduction

Schizophrenia (SZ) is a serious mental disorder that

significantly affects patients’ quality of life (QoL). Its etiology is

still unknown; however, both environmental and genetic factors

play important role. Atypical antipsychotics, fight mainly against

its psychotic symptoms but can also cause various side effects.

Objectives/aims

The study was based on a literature review and

a meta-analysis which revealed pharmacogenomic biomarkers for

the individualization of treatment with atypical antipsychotics.

Main aim was to investigate emerging polymorphisms, in Cau-

casian healthy individuals and schizophrenics.

Materials &methods

Four hundred and eighty-five schizophrenic

patients and 393 matched controls of healthy donors were studied.

Patients were of Greek, Italian, Croatian and Slovenian origin. The

group of patients was divided into two subgroups; TRS (treatment

resistant schizophrenia) and responders in atypical antipsychotics.

Genotyping was performed by Sanger sequencing and PCR/BpEI-

based method.

Results

rs6313 and rs1799978 were indicated as potential

biomarkers of patients’ response on antipsychotics. Experimental

results suggest non-correlation of polymorphisms with patients’

response to these drugs in Greek, Italian, Croatian and Slovenian

populations.

Conclusions

SZ’s etiology is highly complex, however, pharma-

cogenomic studies can lead to the identification of genetic loci

important for disease pathobiology and management as well as

patient stratification. Herein, no correlation was evident regarding

rs6313 and rs1799978 and drug response in the Caucasian popu-

lations studied. Next, sample number will be extended and a more

wide cross-population assessment will occur. Knowledge acquired

and technology improvement, will lead to a better understanding

of the underlying mechanisms, and will subsequently contribute to

the improvement of patients’ QoL.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.683

EW566

Odors hedonic judgment in patients

with schizophrenia. Influence of

negative symptoms and -endorphin

levels

M. Urban-Kowalczyk

Medical University of Lodz, Department of Psychotic and Affective

Disorders, Lodz, Poland

Introduction

The relationship between olfactory and emotional

processing is an area of increasing interest in schizophrenia

research.